1. Improving Limb Salvage for Chronic Limb-Threatening Ischemia With Spinal Cord Stimulation: A Retrospective Analysis
- Author
-
Andreas Paul, Arkadius Pacha, A. Cyrek, Dietrich Koch, Martin Lainka, Nora Henn, and Fabian Meinhardt
- Subjects
Male ,medicine.medical_specialty ,Time Factors ,Arterial disease ,Limb salvage ,Medizin ,Ischemia ,Spinal cord stimulation ,Disease ,Peripheral Arterial Disease ,critical ischemia ,Retrospective analysis ,Humans ,Medicine ,Aged ,Retrospective Studies ,Spinal Cord Stimulation ,Wound Healing ,business.industry ,Microcirculation ,limb salvage ,Recovery of Function ,Original Articles ,General Medicine ,Middle Aged ,medicine.disease ,Surgery ,Functional Status ,Treatment Outcome ,Regional Blood Flow ,Chronic Disease ,Quality of Life ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Introduction: Chronic limb-threatening ischemia (CLTI) represents the most severe form of peripheral artery disease (PAD). Up to a third of CLTI patients are not eligible to receive first-line treatments such as bypass surgery or endovascular interventions. Epidural spinal cord stimulation (SCS) has been used as a method to improve microcirculatory blood flow and relieve ischemic pain in CTLI patients. The aim of the study was to evaluate limb salvage, ulcer closure, and clinical changes of SCS implanted CTLI patients at 1-year follow-up. Methods: Eligible patients had end-stage lower limb PAD unresponsive to medical therapy and not amenable to surgical reconstruction. Patients were candidates for amputation, but limb loss was not inevitable (Fontaine stage III and IV). Pain intensity and skin temperature in the ischemic area (visual analogue scale), quality of life (WHOQoL-BREF), and ankle/brachial blood pressure index (ABI) were recorded at routine follow-up visits. Data were analyzed retrospectively. Results: 29 patients underwent SCS implantation at one vascular center. The minimum follow-up period was 30 months. Limb survival at 1-year follow-up was 97% (28/29) and 73% (11/15) had complete closure of limb ulcers. Pain intensity, skin temperature, and quality of life progressively improved up to 12 months after implant, with Fontaine stage III patients improving more substantially than Fontaine stage IV patients. SCS therapy did not affect ABI measurement. No complications related to the device or procedure occurred. Conclusions: SCS is a valid alternative in patients unsuitable for revascularization. The quality of results depends on both a strict selection of patients by vascular specialists and the frequency of follow-up controls. The therapy may be more beneficial in patients classified as Fontaine stage III.
- Published
- 2021
- Full Text
- View/download PDF